公开(公告)号：EP4175639A1

公开(公告)日：2023-05-10

申请号：EP22733858.9

申请日：2022-05-17

申请人： AB Science

发明人： MOUSSY, Alain ,  MANSFIELD, Colin

IPC分类号： A61K31/496 ,  A61K31/337 ,  A61K31/58 ,  A61K45/06 ,  A61P35/04

公开(公告)号：EP3253749A1

公开(公告)日：2017-12-13

申请号：EP16703138.4

申请日：2016-02-05

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  PEZ, Didier ,  SANDRINELLI, Franck ,  MARTIN, Jason ,  PICOUL, Willy ,  CHEVENIER, Emmanuel

IPC分类号： C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  A61K31/439 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4196 ,  A61K31/4192 ,  A61K31/427 ,  A61P35/00 ,  C07D417/14

CPC分类号： C07D413/10 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/5377 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14

摘要： The present invention relates to compounds of general formula (I). wherein A represents an optionally substituted heterocyclyl group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description. Compounds of formula (I) are useful to destroy, inhibit, or prevent the growth or spread of cells, especially malignant cells, into surrounding tissues implicated in a variety of human and animal diseases

公开(公告)号：EP3240538A1

公开(公告)日：2017-11-08

申请号：EP17712175.3

申请日：2017-03-24

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre ,  MANSFIELD, Colin

IPC分类号： A61K31/496 ,  A61P25/28

CPC分类号： A61K31/496 ,  A61K9/0053 ,  A61K31/428 ,  A61P25/00

摘要： Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is

公开(公告)号：EP2736904B1

公开(公告)日：2016-03-16

申请号：EP12741307.8

申请日：2012-07-24

申请人： AB Science

发明人： BENJAHAD, Abdellah ,  MOUSSY, Alain ,  CHEVENIER, Emmanuel ,  PICOUL, Willy ,  LERMET, Anne ,  PEZ, Didier ,  MARTIN, Jason ,  SANDRINELLI, Franck

IPC分类号： C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  A61P35/00 ,  A61K31/422 ,  A61K31/427

CPC分类号： A61K31/422 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14

公开(公告)号：EP2922572A1

公开(公告)日：2015-09-30

申请号：EP13788783.2

申请日：2013-11-08

申请人： AB Science

发明人： GROS, Laurent ,  DUBREUIL, Patrice ,  MOUSSY, Alain ,  AUDEBERT, Stéphane ,  MANSFIELD, Colin

IPC分类号： A61K45/06 ,  A61K31/496 ,  A61K31/52 ,  A61K31/7068 ,  A61K31/513 ,  A61K31/522 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/706 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/12 ,  A61K31/18 ,  A61K31/22

CPC分类号： A61K31/7068 ,  A61K31/496 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/706 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K45/06 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/395 ,  A61K2300/00

摘要： A method for treating patients afflicted with cancer (including hematological malignancies) or viral infections, wherein the patients are under treatment or are to be treated with at least one anticancer or antiviral agent, and in particular (deoxy)nucleotide or (deoxy)nucleoside analog drugs, includes administering at least one small molecule inhibitor/activator (including ATP competitive inhibitors, signal transduction inhibitors/activators, protein kinase inhibitors/activators, and tyrosine kinase inhibitors/activators) in combination with the (deoxy) nucleotide or (deoxy)nucleoside analog, and wherein the small molecule inhibitor/activator is administered in sufficient amount to modulate deoxynucleotide or deoxynucleoside kinase activity (and in particular deoxycytidine kinase activity) to modulate activation of the (deoxy)nucleotide or (deoxy)nucleoside analog in vivo with a subsequent therapeutically beneficial anticancer or antiviral effect. The combined treatments together include a therapeutically effective amount.

公开(公告)号：EP2903616A1

公开(公告)日：2015-08-12

申请号：EP13773731.8

申请日：2013-10-04

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre ,  PIQUEMAL, David

IPC分类号： A61K31/496 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/496 ,  A61K31/7068 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  A61K2300/00

摘要： The present invention relates to a method for treating patients afflicted with cancer, wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that comprises a therapeutically effective amount. The present invention also relates to methods for predicting therapeutic response to said treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity. The second method is based upon gene expression predictive biomarkers assessed via RNA expression in peripheral blood cell samples collected prior to treatment with a compound of the invention (i.e. a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, especially masitinib). Advantageously, the present invention relates to a method for treating patients afflicted with pancreatic cancer wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and in particular masitinib, optionally in combination with at least one antineoplastic agent, and in particular gemcitabine.

摘要翻译： 一种用于治疗患有癌症的患者，worin患者方法治疗与包括酪氨酸激酶抑制剂，肥大细胞抑制剂或c-kit抑制剂，特别是马赛替尼的化合物，任选地与至少一种抗肿瘤剂。 所述酪氨酸激酶抑制剂，肥大细胞抑制剂或c-kit抑制剂，和任选的至少一种抗肿瘤剂，施用的剂量方案做了包括治疗有效量。 这样描述的是用于预测在给定的患者对治疗的治疗反应，因此鉴定基于合成预测因素适用患者亚群方法; 有时通过向称为生物标志物。 一个方法是基于疼痛强度的临床标志物。 另一种方法是基于通过RNA表达与化合物治疗之前收集外周血细胞样品中预测评定基因表达的生物标志物，从而所有被用于治疗患有胰腺癌折磨的患者。

公开(公告)号：EP2523952B1

公开(公告)日：2015-03-04

申请号：EP11702802.7

申请日：2011-01-12

申请人： AB Science

发明人： MOUSSY, Alain ,  BENJAHAD, Abdellah ,  MARTIN, Jason ,  CHEVENIER, Emmanuel ,  PEZ, Didier ,  SANDRINELLI, Franck ,  PICOUL, Willy

IPC分类号： C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4436 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D413/14 ,  C07D413/12 ,  C07D417/14

公开(公告)号：EP2716767A1

公开(公告)日：2014-04-09

申请号：EP12306209.3

申请日：2012-10-04

申请人： SKULDTECH ,  AB Science

发明人： Piquemal, David ,  Moussy, Alain ,  Kinet, Jean-Pierre ,  Montestruc, François

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158

摘要： The present invention relates to an in vitro method for determining the prognosis of pancreatic cancer in a patient. More particularly, this method comprises the following steps:
c) measuring the expression level of at least two genes chosen in the group consisting in: ING5, RUNDC1, ABCC1, FGFR3, S100A6, ANKRD55, and CD8A or homologous genes, in a blood sample of said patient,
d) predicting the outcome of the pancreatic cancer in said patient.
The invention also relates to a kit specifically designed to carry out such a method.

摘要翻译： 本发明涉及用于确定患者胰腺癌预后的体外方法。 更具体地，该方法包括以下步骤：c）测量在血液样品中选自以下组中的至少两种基因的表达水平：ING5，RUNDC1，ABCC1，FGFR3，S100A6，ANKRD55和CD8A或同源基因 的所述患者，d）预测所述患者中胰腺癌的结果。 本发明还涉及专门设计用于实施这种方法的试剂盒。

公开(公告)号：EP1755592A1

公开(公告)日：2007-02-28

申请号：EP05736673.4

申请日：2005-04-19

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/426 ,  A61K31/421 ,  A61K31/506 ,  A61P21/00

CPC分类号： A61K31/506 ,  A61K31/421 ,  A61K31/426

摘要： The present invention relates to a method for treating inflammatory muscle disorders including myositis and muscular dystrophy comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cell degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

公开(公告)号：EP1478380B1

公开(公告)日：2006-08-02

申请号：EP03712535.8

申请日：2003-02-26

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K38/00

CPC分类号： A61K31/47 ,  A61K31/00 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/66

摘要： The present invention relates to a method for treating CNS disorders, more particularly selected from the group consisting of depression, schizophrenia, anxiety, migraine, memory loss, pain and neurodegenerative diseases, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.